New technology developed to screen for Huntington’s treatments – Drug Target Review

Researchers have created a new technology which enabled them to discover more about the causes of Huntingtons disease and which can be used to test drugs.

A study has used a new technology to understand more about the causations of Huntingtons disease, when the brain is in early developmental stages. According to the researchers, their findings can be used to study the disease and test potential drugs.

The research was conducted at Rockefeller University, US. The new method, in the lab of Professor Ali Brivanlou, uses neuroloids, tiny three-dimensional (3D) tissues cultures, to research cell groupings from human embryonic stem cells. The team was able to manipulate them in the lab to study how the disease arises.

Previous studies conducted by the researchers demonstrated that the condition arises in young neurons, but the new evidence indicates that the disease is caused during neurulation. This is when the brains cellular uniformity changes and distinct structures develop.

Developmental diseases can now be studied with new technology involving tiny brain models called neuruloids, shown here (credit: Laboratory of Stem Cell Biology and Molecular Embryology at The Rockefeller University).

When the researchers introduced into neuroloids a mutation known to cause Huntingtons, it consistently caused abnormally-shaped tissue structures.

The technology is now being used by the researchers to screen for drugs to prevent these abnormalities. They hope that their work will provide an alternative to similar work being done in animal models.

This technology really opens a door toward identifying that mechanisms that govern brain development, understanding how they go awry in disease and testing drugs that set these mechanisms back on the right course, says Brivanlou.

The findings were published in Nature Biotechnology.

Original post:
New technology developed to screen for Huntington's treatments - Drug Target Review

Global Advanced Wound Care Markets to 2024: Emerging Technologies such as Crab Shell Bandages, Bacteriophages, Platelets, and Stem Cell Therapies are…

Dublin, Sept. 17, 2019 (GLOBE NEWSWIRE) -- The "Global Advanced Wound Care Market: Focus on Advanced Wound Care Dressings, NPWT Devices, Wound Care Biologics, HBOT Devices, Ultrasonic Devices, and Electromagnetic Devices - Analysis and Forecast, 2018-2024" report has been added to's offering.

The global advanced wound care market, by-products, was valued to be $8,904.6 million in 2018 and is estimated to reach a market value of $11,059.3 million by 2024 at a CAGR of 3.62% from 2019 to 2024.

The market is subject to intense competition and the rising demand by the governments to reduce spending on healthcare is dragging the market growth. However, future growth is expected to be driven by favorable demographic factors such as the growing aging population and rising incidences of chronic wounds.

Expert Quote

Emerging technologies such as crab shell bandages (involving usage of abundant proteins, chitin, complex hydrogels), bacteriophages, platelets, and stem cell therapy are expected to drive advanced wound care market in future.

However, availability of these technologies in the market is a challenge for key players in the market as these products still need to showcase incremental improvement from current advanced wound care technologies and in order to convince regulators across countries to reimburse these costly treatments such as stem cell therapy.

It will take another 5-10 year for these emerging technologies to significantly capture market share from current technologies.

Scope of the Market

The purpose of this study is to gain a holistic view of the global advanced wound care market in terms of various influencing factors, such as regional adoption trends, and key developments, among others. The scope of this report constitutes an in-depth study of the market, including a thorough analysis of the products across different regions. The report includes an in-depth examination of the key ecosystem players and key strategies and developments taking place in this market. The report presents the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well-informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering into the market.

Market Segmentation

The report on global advanced wound care market tracks trends, industry participants, and quantifies technologies that facilitate wound healing in conditions where standard wound care therapies fail. These technologies are classified under advanced wound dressings, negative pressure wound therapy, wound biologics and an array of emerging technologies such as oxygen therapy, electric simulation, spray mist, and shockwave therapy.

Diving further deep, this report also discusses and quantifies the various underlying conditions for wounds, wound care global burden, and application of advanced wound care in the management of chronic and acute wounds.

The above analysis is conducted at a regional and country level and markets have been sized and forecasted by considering the impact of various trends. Major industry participants and their products have been thoroughly analyzed and forecasts of their performance, market share, and growth rates have been provided. The report considers 2018 as the base year and forecasts the market for the period of 2019-2024.

Key Companies in the Market

Acelity (3M), Smith and Nephew, Molnlycke, ConvaTec, Coloplast, Hartmann, Integra, BSN Medical, MiMedX, Medline and Organogenesis are some of the leading players in this market.

Research Highlights

Key Topics Covered

Executive Summary

1 Product Definition

2 Scope of the Report

3 Research Methodology3.1 Research Methodology3.2 Data Sources3.2.1 Secondary Research Data Sources3.2.2 Primary Data Sources

4 Industry Analysis4.1 Industry Evolution4.2 Wound Management Cost and Supply Chain Analysis4.3 Legal and Regulatory Framework

5 Competitive Landscape5.1 Vendor Share Analysis5.2 Key Strategies and Developments5.2.1 Product Launch and Updates5.2.2 Mergers and Acquisitions5.3 Product Mapping5.4 Competitive Benchmark Mapping

6 Global Advanced Wound Care Market (by Product)6.1 Overview6.2 Advanced Wound Dressing6.2.1 Film Dressing6.2.2 Foam Dressing6.2.3 Hydrofiber Dressing6.2.4 Hydrocolloids Dressing6.2.5 Hydrogel Dressing6.2.6 Collagen Dressing6.2.7 Alginate Dressing6.2.8 Antimicrobial Dressing6.3 Negative Pressure Wound Therapies (NPWT Devices)6.3.1 Conventional Negative Pressure Wound Therapy6.3.1.1 Canisters6.3.1.2 Pumps6.3.1.3 Dressing Kits6.3.2 Single-Use Negative Pressure Wound Therapy6.4 Biologics6.4.1 Skin/Dermal Substitutes6.4.1.1 Allograft6.4.1.2 Xenograft6.4.1.3 Placenta/Amniotic Tissue6.4.1.4 Bioengineered skin/synthetic Substitutes6.4.2 Growth Factors6.4.3 Topical Agents6.5 Other Advanced Wound Care Products6.5.1 Hyperbaric Oxygen Therapy6.5.2 Ultrasonic Mist and Electrical Simulation Devices

7 Global Advanced Wound Care Therapy Market (by Wound type)7.1 Overview7.2 Chronic Wounds7.2.1 Pressure Ulcer (PU)7.2.2 Venous Leg Ulcer (VLU)7.2.3 Diabetic Foot Ulcer (DFU)7.3 Acute Wounds

8 Global Advanced Wound Care Market (by Region)8.1 North America8.1.1 U.S.8.1.2 Canada8.2 Europe8.2.1 U.K.8.2.2 Germany8.3 Asia-Pacific8.3.1 Japan8.3.2 China8.4 Rest-of-the-World (RoW)8.4.1 Brazil

9 Company Profiles9.1 3M9.1.1 Company Overview9.1.2 Role of 3M in the Market9.1.3 Financials9.1.4 SWOT Analysis9.2 Acelity9.3 B. Braun9.4 Coloplast A/S9.5 ConvaTec Group PLC9.6 Essity Aktiebolag9.7 Integra LifeSciences Corporation9.8 Medline Industries, Inc.9.9 Mlnlycke Health Care AB9.10 MIMEDX GROUP, Inc.9.11 Organogenesis Inc.9.12 Osiris Therapeutics Inc.9.13 PAUL HARTMANN AG9.14 Smith & Nephew PLC

For more information about this report visit

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

View post:
Global Advanced Wound Care Markets to 2024: Emerging Technologies such as Crab Shell Bandages, Bacteriophages, Platelets, and Stem Cell Therapies are...

Device can produce synthetic human embryo-like parts – Washington Times

Scientists have developed a device that can produce dozens of synthetic human embryo-like parts simultaneously, calling it a tool that could improve the understanding of early human development.

By making such embryo-like structures from human stem cells, we have now available to us reliable experimental platforms to study human development without using human embryos, said Jianping Fu, one of the studys researchers and an associate professor of mechanical engineering at the University of Michigan.

Using devices that can manipulate fluids, the team of researchers were able to build embryo-like structures that resemble the core of an implanting human embryo, according to their article published last week in the journal Nature.

They created models of the amniotic ectoderm (which develops into the membrane that encloses a developing fetus) and the epiblast (which develops into all the cell types found in the human body) from human stem cells.

But the researchers excluded some important cell types from the embryo-like parts such as the trophoblast, which develops into the placenta, Mr. Fu said.

These embryo-like structures will be very powerful for advancing human embryology and reproductive biology. These embryo-like structures will also be useful for drug and toxicity screens to prevent pregnancy failure and birth defects, Mr. Fu said, adding that the team created them in controllable, reproducible and scalable ways.

The researchers made 12 to 15 embryo-like structures simultaneously at a 95% success rate, he said. Mr. Fu estimates that since 2016 the team has produced a few hundred embryo-like parts, keeping them less than four days.

The research has raised some ethical concerns about the idea of synthetic or artificial embryos, and Mr. Fu said he understands why some people might feel uncomfortable with the concept.

We are well aware of the sensitivity of our research, he said.

But he stressed that what he and the team have created are a mass of cells that mimic portions of a developing embryo that cannot develop into a fetus. He said the research team has no intention of creating a synthetic embryo and has no scientific reason to do so.

Josephine Johnston, director of research and research scholar at the Hastings Center, a bioethics research institute, said the teams study could raise the question of whether the embryo-like structures can be manipulated to create a fetus or whether these scientific techniques are bringing society closer to creating embryos from stem cells, which she described as likely implausible but understandable concerns for the public.

Ms. Johnston also questioned if the word embryo is the correct terminology for Mr. Fus teams work if the structures cannot develop in the womb, cautioning about language use to describe scientific models.

She said the stem cell work, along with cloning research and in vitro fertilization, raise similar concerns about the prospect of embryos having no family structure, and growing them inside peoples bodies and the manipulation of human life. Ms. Johnston added that religious concerns also play a role, which is why there is opposition to in vitro fertilization.

Anytime you are modeling human biology, you are only creating a model. So its never quite the same, and it cant necessarily answer all the same questions, she said of Mr. Fus teams study and the growth of cultured cells in a dish. But it is often a really important intermediary step before moving into doing experiments with humans.

The Fu teams work is the first demonstration of a bona fide human embryo-like structure and shows that such structures can be made from pluripotent or induced pluripotent stem cells in vitro, according to Anna-Katerina Hadjantonakis, a developmental biologist for the Sloan Kettering Institute.

Whats important is that this method is very robust and reproducible. Many identical structures can be generated at once, all having similar morphology which approximates to the human embryo, she said. The work opens the door and provides an accessible method for future studies in other laboratories.

Mr. Fu said he and the team are interested in continuing to polish the stem cell in vitro system using fluid-controlling devices to prolong the culture of human embryo-like structures.

He said other scientists have been able to create structures that resemble complete mouse embryos and implant those synthetic embryos into a surrogate. However, there has been no further development of artificial animal embryos beyond early implantation, he said.

Mr. Fu said he and his group created a 3D culture system using human stem cells two years ago. Other scientists have reported building 3D systems using mouse and human stem cells.

Sign up for Daily Newsletters

Follow this link:
Device can produce synthetic human embryo-like parts - Washington Times

Couple give embryos, ‘hope’ to UM in fight against rare disease – The Detroit News

Alexandra Cellucci was 28 when she was diagnosed with neurofibromatosis, a rare genetic disease that causes noncancerous tumors to growon thebody's nervous tissues. She was also eight months pregnant at the time, but she would eventually delivera healthy baby girl.

Neurofibromatosis,known as NF for short,runs in Cellucci'sfamily, so sheknew her daughter could have the diseaseand she could pass it on to futurechildren. So sheand her husband, Marc, used reproductive medicine to conceive another baby, hadthe embryostested for the gene that causes NFand had doctors implantembryos in her womb without the mutatedgene.

Alex Cellucci, 35, rubs fabric on her right eye, where she had a tumor removed the previous day, while watching a movie with her daughter, Maible, 6, at their home in Quincy, Mass. on Tuesday, Aug. 6, 2019. Alex and Maible both have neurofibromatosis, a genetic disorder that causes tumors to form on nerve tissue. Alex was diagnosed with neurofibromatosis type 2 at age 28 and has since endured two MRI scans every year to monitor tumors.(Photo: Nic Antaya, Special to The Detroit News)

Cellucci, now 35, never got pregnant again, despite many attempts. She and her husband have since learned their daughter Maible, now6,also carriesthe gene for NF2, one of the three forms of the disease. The day before Maible's birthday last November,the girl asked if she had the disease. Cellucci said she told her yes and that she would be OK.

That's why the Massachusetts coupledonated seven embryos with the NF2 gene to the University of Michigan soresearchers could create an embryonic stem cell line that other researchers could study, with the hope of one day discovering a breakthrough. In a perfect world, such a development would come before their daughter endures any symptoms.

Alex Cellucci, 35, poses for a portrait at her home in Quincy, Mass. on Tuesday, Aug. 6, 2019. Alex and her 6-year-old daughter, Maible, both have neurofibromatosis, a genetic disorder that causes tumors to form on nerve tissue.(Photo: Nic Antaya, Special to The Detroit News)

I just wanted hope," said Cellucci, who had surgery last monthto remove a benigntumorbehind her eye. "They could possibly find a cure for (Maible) ... and offer hope for other families."

UM researchers have turned the Celluccis' embryos intothe firststem cell line that models NF2, which is one of the more rare forms of the disease. Besides the tumor growth, NF2 comes with a host of issues, including hearing loss, ringing in the ears and loss of balance. Symptoms typically appear in the teen years.

The embryonic stem cell line modeling the disease, created by ProfessorGary Smith, director ofthe MStem Cell Laboratories,has been acceptedonto the National Institutes of Health Human Embryonic Stem Cell Registryforother scientists to study and make discoveries around interventions anda possible cure. Another line also is under review.

Alex Cellucci, 35, watches a movie at her home in Quincy, Mass., a day after having a tumor removed from behind her right eye.(Photo: Nic Antaya, Special to The Detroit News)

Researchers can apply to access the stem cell lines on thefederal registryto study how diseases form and develop, with the aim of finding ways to better understand, treat, delay and possibly even cure diseases.

Smith has derived all of UM's56embryonic stem cell lines on the national registry, including 36 disease-specific lines. Hesaid the personal stories behind all of those stem cell lines are important.

"We just don't do science to do science," Smith said. "We do science to help others. Here is a family that recognizes that. Sometimes that gets lost on people. ... We really do want to help people."

The NF2 stem cell line comes as neurofibromatosis scientists andclinicians prepare to gather next month for their annual conference in San Francisco.

Alex Cellucci, 35, and her daughter, Maible, 6, watch a movie at their home in Quincy, Mass. on Tuesday, Aug. 6, 2019. Alex and Maible both have neurofibromatosis, a genetic disorder that causes tumors to form on nerve tissue. Alex was diagnosed with neurofibromatosis type 2 at age 28 and has since had two MRI scans done every year to monitor tumors. Most recently, Alex had a tumor removed behind her right eye on Aug. 5, 2019.(Photo: Nic Antaya, Special to The Detroit News)

It also comes as Detroitbusinessman andCleveland Cavaliers ownerDan Gilbert has used philanthropy to support the small research community of neurofibromatosis. His 23-year-old son, Nick, was born with neurofibromatosis type 1.

NF2 afflicts1 in 33,000 people worldwide, while NF1 is more common, occurringin 1 in 3,000 to 4,000 people, according to the National Institutes of Health. NF1 typically begins in childhood and leads to skin changes and bone deformity.Schwannomatosis, the rarest type of NF, causes intense pain.

Gilbert, who suffered a stroke in late May,has spoken about neurofibromatosis and also about howNick, a Michigan State University student, hadto undergobrain surgery in 2018 to remove tumors.

Gilbert, a billionaire, has invested $64 million over the yearsthrough the Gilbert Family Foundation, including $12 million for gene therapy initiatives to address the underlying cause of NF1 and $11 million for vision loss in NF1 patients, which Nick grapples with, according toYooRi Kim, the foundation's scientific officer.

Marc and Alex Cellucci, and their daughter, Maible, 6, and dog Pedalino, pose for a portrait outside of their home in Quincy, Mass. on Tuesday, Aug. 6, 2019. Alex and Maible both have neurofibromatosis, a genetic disorder that causes tumors to form on nerve tissue.(Photo: Nic Antaya, Special to The Detroit News)

"With deeper understanding with each of these diseases that we've obtained over time, it's becoming more and more clear that the strategies that you would use to help each of thosepatients are going to look different," Kim said.

Even so, she said there is excitement about advances in research on other forms of NF, such as the stem cell line modeling NF2.

There arefour embryonic stem cell lines on the registry that model NF1, but theline UM created is the first for the research community studying NF2,according to Smith.

"It means a lot to the couplethat somebody is using something that otherwise would have been discarded and instead trying to make it something that can be used worldwide to understand this disease better," he said.

The stem cell line hasbeen applauded by Sally Temple, scientific director of the Neural Stem Cell Institute in Rensselaer,New York, which uses stem cell technologies to develop therapies that affect the nervous system.

Alex Cellucci, 35, and her daughter, Maible, 6, pose for a portrait outside of their home in Quincy, Mass. on Tuesday, Aug. 6, 2019. Alex and Maible, both have neurofibromatosis, a genetic disorder that causes tumors to form on nerve tissue.(Photo: Nic Antaya, Special to The Detroit News)

"It's a really wonderful and generous for the parents to do," said Temple, who is also aUM adjunct professor in the ophthalmology department. "When you make these human embryonic stem cell lines, they are essentially a resource forever for the community. It's available and it will be there for (researchers)to use forever in the future. It's not a one-time donation."

She added that this is important for the NF2 community since it is such a devastating disease.

Marc Cellucci is beyond thrilled, and hopeful of the possibilities for the stem cell line that he and his wife helped create and what it could do for his daughter, wife, in-laws and so many others with NF.

It all has to start somewhere, said Cellucci,where the scientific breakthroughs happen, and the miracles begin.

Read or Share this story:

Read the original:
Couple give embryos, 'hope' to UM in fight against rare disease - The Detroit News

Growth of the Global Cord Blood Stem Cell Market Driven by Improvements in Product Design – Business Broker

A new global Cord Blood Stem Cell market research report is a in-depth study of Cord Blood Stem Cell industry including essential frameworks. Global Cord Blood Stem Cell Market Report highlights market revenue, share, growth and market size. Also accentuate industry contribution, product image and provision. It scrutinize a competitive summary of market between forecast period 2019 to 2028.

The Global Cord Blood Stem Cell Market report includes a overall industry outline to provide clients with a entire idea of Cord Blood Stem Cell market situation and its strategies. The insight review of the research is followed by segmentation, application and region wise analysis of the market to insure that clients are well proficient about each section. Thisreport also includes main point and facts of Global Cord Blood Stem Cell Market with its sales and growth.

Click to get sample copy of report @

The report collect all the Cord Blood Stem Cell industry information from primary and secondary sources. Further, segmented the Cord Blood Stem Cell market into major applications, types and key vendors around the globe. The major Cord Blood Stem Cell market players includes Lifecell International Pvt. Ltd., Viacord Inc., Cryo-Cell International Inc, Cryo-Save AG., Cord Blood Registry Systems Inc, China Cord Blood Corporation., Cord Blood America Inc, Vita 34 AG., Stemcyte Inc. and Cordlife Group Ltd.. geographically the region cover in Cord Blood Stem Cell market are Asia-Pacific, Latin America, North America, Europe and the Middle East & Africa.

The segmentation outlook for world Cord Blood Stem Cell market report:

Cord blood stem cell market segmentation by storage service:

Public cord blood bankPrivate cord blood bankCord blood stem cell market segmentation by application:

Blood diseaseCancerAcute leukaemiaKrabbe diseasesOther diseases

The research Cord Blood Stem Cell report will enhance your decision-making power by helping you to

Enhancing market activities by proper structuring your product development and designing sales strategies.

Clear understanding the market dynamics and developments to develop business strategies.

Found new market strategies and efficient ways to assist competition.

Cord Blood Stem Cell report helps to create merger and acquistion opportunities by analysing the market vendors.

Analyse the region wisemarket potential which helps to design region wise strategies.

Understand the competitive outline in the global Cord Blood Stem Cell market.

Take important business decisions by trusting on the astute opinions from Cord Blood Stem Cell industry expertise.

Click to inquire for report @

Why MarketResearch.Biz ?

Technically renowned study with overall Cord Blood Stem Cell industry knowhow.

Robust research methodology of Cord Blood Stem Cell market.

Based on complete research, we offer clear view of real Cord Blood Stem Cell market scenario and help clients with making important business judgement.

Comprehensive archive of Cord Blood Stem Cell market research reports to meet our clients needs.

Focus on Cord Blood Stem Cell drivers, restraints, opportunities, and threats till 2028.

Shortly, Cord Blood Stem Cell report claims about historical, present and foresee Cord Blood Stem Cell market impulses.

Media Contact:

Mr. Benni Johnson

MarketResearch.Biz (Powered By Prudour Pvt. Ltd.)

420 Lexington Avenue, Suite 300, New York City, NY 10170, United States

Tel: +1 347 826 1876

Email ID

Visit link:
Growth of the Global Cord Blood Stem Cell Market Driven by Improvements in Product Design - Business Broker

Research: By exploiting a feature of the immune system, researchers open the door for stem cell transplants to repair the brain – Tdnews

In experiments in mice, Johns Hopkins Medicine researchers say they have developed a way to successfully transplant certain protective brain cells without the need for lifelong anti-rejection drugs.

A report on the research, published Sept. 16 in the journal Brain, details the new approach, which selectively circumvents the immune response against foreign cells, allowing transplanted cells to survive, thrive and protect brain tissue long after stopping immune-suppressing drugs.

The ability to successfully transplant healthy cells into the brain without the need for conventional anti-rejection drugs could advance the search for therapies that help children born with a rare but devastating class of genetic diseases in which myelin, the protective coating around neurons that helps them send messages, does not form normally. Approximately 1 of every 100,000 children born in the U.S. will have one of these diseases, such as Pelizaeus-Merzbacher disease. This disorder is characterized by infants missing developmental milestones such as sitting and walking, having involuntary muscle spasms, and potentially experiencing partial paralysis of the arms and legs, all caused by a genetic mutation in the genes that form myelin.

Because these conditions are initiated by a mutation causing dysfunction in one type of cell, they present a good target for cell therapies, which involve transplanting healthy cells or cells engineered to not have a condition to take over for the diseased, damaged or missing cells, says Piotr Walczak, M.D., Ph.D., associate professor of radiology and radiological science at the Johns Hopkins University School of Medicine.

A major obstacle to our ability to replace these defective cells is the mammalian immune system. The immune system works by rapidly identifying self or nonself tissues, and mounting attacks to destroy nonself or foreign invaders. While beneficial when targeting bacteria or viruses, it is a major hurdle for transplanted organs, tissue or cells, which are also flagged for destruction. Traditional anti-rejection drugs that broadly and unspecifically tamp down the immune system altogether frequently work to fend off tissue rejection, but leave patients vulnerable to infection and other side effects. Patients need to remain on these drugs indefinitely.

In a bid to stop the immune response without the side effects, the Johns Hopkins Medicine team sought ways to manipulate T cells, the systems elite infection-fighting force that attacks foreign invaders.

Specifically, Walczak and his team focused on the series of so-called costimulatory signals that T cells must encounter in order to begin an attack.

These signals are in place to help ensure these immune system cells do not go rogue, attacking the bodys own healthy tissues, says Gerald Brandacher, M.D., professor of plastic and reconstructive surgery and scientific director of the Vascularized Composite Allotransplantation Research Laboratory at the Johns Hopkins University School of Medicine and co-author of this study.

The idea, he says, was to exploit the natural tendencies of these costimulatory signals as a means of training the immune system to eventually accept transplanted cells as self permanently.

To do that, the investigators used two antibodies, CTLA4-Ig and anti-CD154, which keep T cells from beginning an attack when encountering foreign particles by binding to the T cell surface, essentially blocking the go signal. This combination has previously been used successfully to block rejection of solid organ transplants in animals, but had not yet been tested for cell transplants to repair myelin in the brain, says Walczak.

In a key set of experiments, Walczak and his team injected mouse brains with the protective glial cells that produce the myelin sheath that surrounds neurons. These specific cells were genetically engineered to glow so the researchers could keep tabs on them.

The researchers then transplanted the glial cells into three types of mice: mice genetically engineered to not form the glial cells that create the myelin sheath, normal mice and mice bred to be unable to mount an immune response.

Then the researchers used the antibodies to block an immune response, stopping treatment after six days.

Each day, the researchers used a specialized camera that could detect the glowing cells and capture pictures of the mouse brains, looking for the relative presence or absence of the transplanted glial cells. Cells transplanted into control mice that did not receive the antibody treatment immediately began to die off, and their glow was no longer detected by the camera by day 21.

The mice that received the antibody treatment maintained significant levels of transplanted glial cells for over 203 days, showing they were not killed by the mouses T cells even in the absence of treatment.

The fact that any glow remained showed us that cells had survived transplantation, even long after stopping the treatment, says Shen Li, M.D., lead author of the study. We interpret this result as a success in selectively blocking the immune systems T cells from killing the transplanted cells.

The next step was to see whether the transplanted glial cells survived well enough to do what glial cells normally do in the brain create the myelin sheath. To do this, the researchers looked for key structural differences between mouse brains with thriving glial cells and those without, using MRI images. In the images, the researchers saw that the cells in the treated animals were indeed populating the appropriate parts of the brain.

Their results confirmed that the transplanted cells were able to thrive and assume their normal function of protecting neurons in the brain.

Walczak cautioned that these results are preliminary. They were able to deliver these cells and allow them to thrive in a localized portion of the mouse brain.

In the future, they hope to combine their findings with studies on cell delivery methods to the brain to help repair the brain more globally.

Other researchers involved in this study include Byoung Chol Oh, Chengyan Chu, Antje Arnold, Anna Jablonska, Georg Furtmller, Huamin Qin and Miroslaw Janowski of The Johns Hopkins University; Shen Li of the Dalian Municipal Central Hospital and The Johns Hopkins University; Johannes Boltze of the University of Warwick; and Tim Magnus and Peter Ludewig of the University of Hamburg.

This research was funded by the National Institute on Neurological Disorders and Stroke (R01NS091110, R01NS091100, R01NS102675, 2017-MSCRFD-3942).

See the article here:
Research: By exploiting a feature of the immune system, researchers open the door for stem cell transplants to repair the brain - Tdnews

Induced Pluripotent Stem Cell Market Estimated to be Driven by Innovation and Industrialization – Wolf Mirror

Overview of the iPS Cell Market with Reference to the Global Healthcare Sector Outlook

Despite the economic and political uncertainty in the recent past, the global healthcare industry has been receiving positive nudges from reformative and technological disruptions in medical devices, pharmaceuticals and biotech, in-vitro diagnostics, and medical imaging. Key markets across the world are facing a massive rise in demand for critical care services that are pushing global healthcare spending levels to unimaginable limits.

A rapidly multiplying geriatric population; increasing prevalence of chronic ailments such as cancer and cardiac disease; growing awareness among patients; and heavy investments in clinical innovation are just some of the factors that are impacting the performance of the global healthcare industry. Proactive measures such as healthcare cost containment, primary care delivery, innovation in medical procedures (3-D printing, blockchain, and robotic surgery to name a few), safe and effective drug delivery, and well-defined healthcare regulatory compliance models are targeted at placing the sector on a high growth trajectory across key regional markets.

Parent Indicators Healthcare Current expenditure on health, % of gross domestic product Current expenditure on health, per capita, US$ purchasing power parities (current prices, current PPPs) Annual growth rate of current expenditure on health, per capita, in real terms Out-of-pocket expenditure, % of current expenditure on health Out-of-pocket expenditure, per capita, US$ purchasing power parity (current prices, current PPPs) Physicians, Density per 1000 population (head counts) Nurses, Density per 1000 population (head counts) Total hospital beds, per 1000 population Curative (acute) care beds, per 1000 population Medical technology, Magnetic Resonance Imaging units, total, per million population Medical technology, Computed Tomography scanners, total, per million population

Research Methodology

Get Sample Copy of this report at

XploreMR utilizes a triangulation methodology that is primarily based on overall expenditure on life science research and R&D funding and capital equipment installed base to obtain precise market estimations and insights on life science and biotechnology associated products, technologies, applications and services. Bottom-up approach is always used to obtain insightful data for the specific country/regions. The country-specific data is again analysed to derive data at a global level. This methodology ensures high quality and accuracy of information.

Secondary research is used at the initial phase to identify the feasibility of the target products/technology categories and its respective segments, product and service offerings, equipment installed base in end use facilities, adoption rate and future impact of new technologies. Additionally, per capita consumption of kits, reagents and consumables among end users is tracked at a granular level to obtain the most accurate information. Each piece of information is eventually analysed during the entire research project which builds a strong base for the primary research information.

Primary research participants include demand-side respondents such as laboratory managers, procurement managers, research supervisors at academic and research institutes, as well as key opinion leaders in addition to supply-side respondents such as equipment and reagent manufacturers, custom solution and service providers who provide valuable insights on trends, research application of products and technologies, purchasing patterns, services offered and associated pricing.

Quantitative and qualitative assessment of basic factors driving demand, economic factors/cycles and growth rates and strategies utilized by key players in the market is analysed in detail while forecasting, in order to project year-on-year growth rates. These Y-o-Y growth projections are checked and aligned as per associated industry/product lifecycles and further utilized to develop market numbers at a holistic level.

On the other hand, we also analyse annual reports of various companies, investor presentations, SEC filings, 10k reports and earning call transcripts operating in the market to fetch substantial information about the market size, trends, opportunity, drivers, restraints and to analyse key players and their market shares. Key companies are segmented at tier-level based on their revenues, product portfolio and presence.

Please note that these are the partial steps that are being followed while developing the market size. Besides this, forecasting will be done based on our internal proprietary model which also uses different macro-economic factors such as overall life science research expenditure, R&D funding, industry based demand driving factors impacting the market and its forecast trends apart from other macroeconomic factors.

Browse Full Report at

Standard Report Structure Executive Summary Market Definition Macro-economic analysis Parent Market Analysis Market Overview Forecast Factors Segmental Analysis and Forecast Regional Analysis Competition Analysis

Market Taxonomy

The global iPS cell market has been segmented into:

Cell Type Hepatocytes Fibroblasts Keratinocytes Neurons Others

Application Drug Development Regenerative Medicine Toxicity Testing

End User Academic and Research Institutes Biotechnology Companies

Region North America Latin America Europe Asia Pacific excluding China (APEC) China Middle East and Africa (MEA)

Buy Full Report at

Read more:
Induced Pluripotent Stem Cell Market Estimated to be Driven by Innovation and Industrialization - Wolf Mirror

Study Of Stem Cell Cartilage Regeneration Market And Also Elements For Its Future Growth 2026 – Coherent Magazine

***The operating environment for global organizations is increasingly getting complex. This has left organizations playing catch-up with constantly emerging new business strategies. There is a growing demand for the inclusion of best-consulting services in sync with the organizations business strategy. The transformation of functional areas can and should be integrated into every industry. At Coherent Market Insights, we closely interact with our clients to meticulously examine their business consulting needs and accordingly offer tailored solutions through our unmatched business insights and analytics. ***

Coherent Market Insightsnow offers a detailed analysis of theStem Cell Cartilage Regeneration Marketin new research that provides valuable business insights including revenue share, market valuation, and regional spectrum of this vertical. The report is an all-inclusive study of the current market trends, potential drivers and challenges, application landscape, competition situation, and industry-popular growth strategies, which will empower stakeholders to obtain a clear understanding of this domain. This report also provides precise information pertaining to market size, commercialization aspects and revenue estimation of this business. The report further elucidates the status of leading industry players thriving in the competitive spectrum of the Stem Cell Cartilage Regeneration Market.

The PDF for the study can be requested using the following link:

The latest study on Stem Cell Cartilage Regeneration Market is a compilation of in-depth dissection of this business vertical that is projected to attain commendable proceeds during the estimated timeline, recording momentous yearly growth rate through the anticipated duration. The study precisely inspects the Stem Cell Cartilage Regeneration Market and in doing so, it dispenses valuable insights with respect to industry size, revenue approximations, sales capacity, and more. Additionally, the report also examines the segments alongside the driving forces behind the commercialization portfolio of this business.


Stem cells therapy are emerging as an important therapeutic option in the field of cartilage regeneration. Rapid development of stem cell-based therapy for cartilage regeneration in the recent past has been witnessed across the world. Stem cells are mainly classified in three kinds of cells: hematopoietic stem cell, mesenchymal stem cells, and pluripotent stem cells.

The global stem cell cartilage regeneration market size was valued atUS$ 254.4 millionin 2017, and is expected to witness a CAGR of 8.9%over the forecast period (2018 2026).

One of the key factors that make this report worth a purchase is the extensive outline it presents, pertaining to the competitive landscape of the industry. The study, on the basis of the competitive landscape, segments the market into the companies such asTheracell Advanced Biotechnology Ltd., Orthocell Ltd., Xintela AB, CellGenix GmbH, Merck KGaA, Osiris Therapeutics, Inc., BioTissue SA, and Vericel Corporation.. These firms, as is observed, consistently vie with one another in order to accomplish a successful position in the industry.

The key region covered in this report are:

North America:United States, Canada, Mexico

Europe:Germany, France, UK, Russia, Italy, Rest of Europe

Middle East Africa:Turkey, Egypt, South Africa, GCC Countries, Rest of Middle East & Africa

Asia-Pacific:China, India, Australia, Japan, South Korea, Indonesia, Malaysia, Philippines, Thailand, Vietnam

A brief outline of the Stem Cell Cartilage Regeneration Market scope:

Additional key understandings mentioned in the report have been listed below:

If you wish to find more details of the report or want customization, contact us. You can get a detailed of the entire research here. If you have any special requirements, please let us know and we will offer you the report as you want.

We Offer Customized Report, Click @

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

See the original post:
Study Of Stem Cell Cartilage Regeneration Market And Also Elements For Its Future Growth 2026 - Coherent Magazine

Global Stem Cell Therapy Market Expects an Extensive Growth in ROI of USD 4759.27 Million By 2024 – News Hours Today

Zion Market Researchpublished a new industry research reportGlobal Stem Cell Therapy Market Set For Rapid Growth, To Reach Around USD 4759.27 Million By 2024in its database.(Sample Copy Here)The global Stem Cell Therapy Market report provides significant information about Stem Cell Therapy Market by fragmenting the market into different segments.This study assists users in decoding the finest distinctions of regional as well as global markets while they enlarge their global reach.The Stem Cell Therapy Market report updates the user about various market growth strategies and management. It states the various terminologies used in the global Stem Cell Therapy Market. The globalStem Cell Therapy Marketreport covers data over the industries and markets, technologies and abilities of the market. It collects the facts and figures over the revenue of the global market and conditions. The report provides the explanation related to the market values and potential market players future scope.

Request Sample ofStem Cell Therapy MarketReport for more

Global Stem Cell Therapy Market competition by top manufacturers/players, sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including:

The company profile also includes a company overview, revenue information, and product overview. This section helps to understand businesses operating in the industry to understand the strategies of the key players and the factors that are helping them excel in the industry. The competitive scenario is also useful for the new entrants in the business to know their competitors as well as their business plans.

The Stem Cell Therapy Market report gathers the realistic data about the well-known participants in the global market together with their contribution of share in the global market. This data works as a useful tool to estimate their progress for the particular time period. The global Stem Cell Therapy Market report gathers data from the prominent institution of the global Stem Cell Therapy Market.

Get Brochure of thisStem Cell Therapy

Attributes and market execution are investigated using quantitative and qualitative techniques to give a clear picture of current and future growth trends. A precise market analysis based on geographic locations is also presented in this report. The global Stem Cell Therapy Market report offers the data diagrams, figures, and collateral that illustrates the state of the specific trade in the local and global scenario.

Promising Regions & Countries Mentioned In The Stem Cell Therapy Market Report:

The data offered in the report will assist the customers in improving their ability to make precise decisions related to the business under Stem Cell Therapy Market. The report also focuses on the ongoing and upcoming regulations and policies to be introduced by the government bodies, which may enhance or suppress the market growth. For making the information better understanding, the analysts and professionals have incorporated diagrams, statistical figures, flow charts, and examples in the global Stem Cell Therapy Market report. Along with this, the report delivers analytical information through segmentation of the market at a geographical level.At last, the global Stem Cell Therapy Market gives the readers a complete view of the market during the forecast period from 2018-2025 which will assist them in making right business choices that will lead to development the development of their company.

Browse Press

Available Array of Customizations:

The report similarly expresses the numerous possibilities for the advancement of the market in the upcoming period. It also highlights earlier trends in the global Stem Cell Therapy Market. For the assessment of the development of the market in the anticipated period, a few insightful techniques are utilized in the study. The global Stem Cell Therapy Market analysis is done based on revenue [USD Million] and size [k.MT] of the market.

Purposes Behind Buying Stem Cell Therapy Market Report:-

The classification of the global Stem Cell Therapy Market is done based on the product type, segments, and end-users. The report provides an analysis of each segment together with the prediction of their development in the upcoming period. Additionally, the latest research report studies various segments of the global Stem Cell Therapy Market in the anticipated period.

Also, Research Report Examines:

Lastly, with a team of vivacious industry professionals, we offer our clients with high-value market research that, in turn, would aid them to decipher new market avenues together with new strategies to take hold of the market share.

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia

Read this article:
Global Stem Cell Therapy Market Expects an Extensive Growth in ROI of USD 4759.27 Million By 2024 - News Hours Today

Attorney General trying to intimidate witness testifying about live fetal hearts: lawyers – Lifesite

SAN FRANCISCO, California, September 17, 2019 (LifeSiteNews) Lawyers for pro-life journalists David Daleiden and Sandra Merritt are accusing Californias deputy attorney general of trying to intimidate and threaten a critical expert witness.

Dr. Theresa Deisher, an expert in stem cell research at Stanford University, is set to testify for the defense Wednesday.

But Deputy Attorney General Johnette Jauron asked Daleiden on cross-examination Monday if Deisher was party to the undercover operation that led to his and Sandra Merritts criminal prosecution.

Daleiden and Merritt of the Center for Medical Progress (CMP) are charged with 14 felony counts of illegal recording in connection with undercover videos CMP released in 2015 that exposed Planned Parenthoods trafficking in aborted baby body parts. Originally they were charged with 15 felony counts, but one of those charges was dropped Friday.

Daleiden testified that he consulted Deisher only about the science of stem cell research, and that she was not privy to his covert investigation.

In earlier testimony, Daleiden said he asked Deisher and other experts whether a 2102 Stanford study in which aborted baby hearts supplied by StemExpress that were perfused in a Langendorff apparatus would require that the hearts be beating.

Dr. Deisher told me the fetus would have to be alive at the time the organs were harvested for use in the Langendorff apparatus, he told the court.

In light of Jaurons questions, Judge Christopher C. Hite told defense counsel Tuesday that Deisher might need to consult a lawyer regarding her testimony, since the attorney general had raised the possibility of a prosecution against her.

Defense lawyers swiftly rejected the idea.

Its absurd, and a waste of time, Daleidens lawyer Brentford Ferreira told the court.

I believe this is being done to intimidate the witness.

Horatio Mihet of Liberty Counsel, a lawyer for Merritt, also blasted the ridiculousness of the suggestion Deisher needed a lawyer.

Hite, however, told them that he couldnt ignore that they may or may not prosecute and that it was within his discretion as a judge to counsel Deisher to seek legal advice.

When Deisher was sworn in as a witness just before the court adjourned on Tuesday, the judge told her he had information that would compel me to advise you you have the right to seek an attorney.

It is not clear at this time if Deisher has done so.

Nicolai Cocis, a California attorney who is representing Merritt, excoriated the move.

Essentially the attorney general is threatening a critical witness with prosecution if she testifies, he told LifeSiteNews.

They think that David and she conspired, Cocis said. But they havent talked to her directly.

If I, as a defense lawyer, threatened a prosecution witness the way they are threatening our defense witness, I would be facing criminal charges, he added.

Jauron asked Daleiden on cross-examination Tuesday about Deisher being listed as one of his project consultants in his January 2013 proposal for an in-depth undercover investigation into the illegal trafficking in aborted baby body parts.

Deisher was listed in my project for donors as one of my experts in stem cell research, Daleiden said.

She, in fact, consulted with you in anticipation of your investigation, Jauron said.

Daleiden replied that during the time he was preparing himself and his investigative team for the undercover operation, he asked Deisher scientific questions to be thoroughly conversant with the stem cell research and fetal tissue procurement field.

He testified that he met Deisher in 2010, and talked to her on the phone about four times a year from 2010 to 2014. He had a couple more detailed discussions with her about some of the conversations he and Merritt recorded in 2014 before the videos were released.

He believed Deisher was provided with some videos through defense counsel for her role as an expert witness in the case, Daleiden told the court.

Jauron asked Daleiden if he paid Deisher, and he said no.

Deisher is expected to testify Wednesday morning.

Read this article:
Attorney General trying to intimidate witness testifying about live fetal hearts: lawyers - Lifesite